 |
|
|
   
|
LONG BEACH, Calif., September 20, 2006– Obagi Medical Products, Inc. (OMP), a
leader in developing and marketing specialty skin health products to physicians,
has initiated a multi-center, randomized-blinded clinical study evaluating wound
healing and scar cosmesis in patients with superficial basal cell carcinoma
(sBCC) when using their Nu-Derm® Condition and Enhance System before and after
electrodessication and curettage (ED&C).
The study’s treatment protocol was structured in cooperation with the key
Clinical Investigators, Drs. David M. Pariser, James M. Spencer, Kenneth G.
Gross, Suzanne Bruce and Robert Loss. "Treatment of superficial basal cell
carcinoma by ED&C is a commonly performed procedure by almost all
dermatologists. Any well designed study that demonstrates a way to accelerate
healing and decrease scarring will be a welcome development", said Dr. Pariser,
Director of the Virginia Clinical Research, Inc and Professor of Dermatology at
Eastern Virginia Medical School in Norfolk, Virginia
Steve Carlson, OMP’s CEO states, “Based on the anecdotal clinical reports from
numerous physicians both domestically and internationally, OMP anticipates this
clinical study will demonstrate increased rates of re-epithelialization,
improved healing, and better wound cosmesis with the use of the Nu-Derm®
System. Ultimately, our goal as a Company, is to improve the patient outcome
and this study will help define more appropriate therapeutic approaches to wound
healing”.
About Obagi Medical Products, Inc.
Obagi (www.obagi.com) is a specialty pharmaceutical company that develops and
commercializes skin health products for the dermatology, plastic surgery, and
related Aesthetic and Therapeutic skin health markets. Obagi’s products are
designed to improve penetration of active agents across the skin barrier for the
prevention and correction of the most common and visible skin disorders in adult
skin such as chloasma, melasma, senile lentigines, acne vulgaris and sun damage.
Obagi launched its first skincare system, Obagi Nu-Derm, in 1988; and in 2004
launched the first and only prescription strength Vitamin C and hydroquinone
system, Obagi-C Rx. Obagi launched a new line of Professional-C Serums, in
concentrations of 5%, 10%, 15%, and 20% L-ascorbic acid to provide a range of
antioxidant treatments to patients. Obagi System products are only available
through physicians, primarily Plastic Surgeons and Dermatologists.
|
|
|
|